Reuters logo
U.S. FDA advisers recommend Mannkind's inhaled diabetes drug Afrezza
April 1, 2014 / 8:57 PM / 3 years ago

U.S. FDA advisers recommend Mannkind's inhaled diabetes drug Afrezza

HYATTSVILLE, Md., April 1 (Reuters) - Mannkind Corp’s inhaled diabetes drug Afrezza is safe and effective for diabetes patients with either the type 1 or type 2 form of the disease, U.S. health advisers said on Tuesday in recommending its approval for sales in the United States.

The Food and Drug Administration’s advisory panel, in a 13-1 vote, backed the rapid-acting insulin treatment for adults with type 1 diabetes. In a 14-0 vote, it also supported Afrezza treatment for adults with the more common type 2 form of the disease.

The FDA, which does not have to follow its panel’s advice, is expected to make its approval decision by April 15. (Reporting by Susan Heavey; Editing by Peter Cooney)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below